Therapy of chronic hepatitis B virus infection: Inhibition of the viral polymerase and other antiviral strategies

Antiviral Research

Volumn 44, Issue 1, 1999, Pages 1-30

  Zoulim, Fabien ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

Antiviral therapy; Chronic hepatitis B; Hepadnaviridae; Hepatitis B virus; Nucleoside analogs; Viral resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CYTIDINE DERIVATIVE; DEOXYGUANOSINE DERIVATIVE; ENTECAVIR; FAMCICLOVIR; FOSCARNET; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE;

ANTIMICROBIAL THERAPY; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

DNA VIRUSES; HEPADNAVIRIDAE; HEPATITIS B VIRUS;

EID: 0032701683     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00056-X     Document Type: Article

References (223)

1. Aguesse, S., Wang, Z., Boulay, A., Dannaoui, E., Borel, C., Schinazi, R., Cheng, Y.C., Trépo, C., Zoulim, F., 1997. An in vitro assay for the determination of the mechanism of inhibition of hepatitis B virus replication by nucleoside analogs and non nucleoside inhibitors. Viral hepatitis and liver disease. In: Rizzetto, M., Purcell, R.H., Gerin, J.L., Verme, G. (Eds.), Proceedings of the IX International Symposium of Viral Hepatitis and Liver Disease, Rome, April 1996, Edizioni Minerva Medica, Turin, pp. 152-156.
2. Aguesse-Germon S., Liu S.-H., Chevallier M., Pichoud C., Jamard C., Borel C., Chu C.K., Trépo C., Cheng Y.-C., Zoulim F. Inhibitory effect of 2′-fluoro-5-methyl-β-L-arabinofuranosyl-uracyl on duck hepatitis B virus replication. Antimicrob. Agents. Chemother. 42:1998;369-376.
3. Aguesse-Germon, S., Seignères, B., Pichoud, C., Trépo, C., Zoulim, F., 1999. Replication capacity and sensitivity to nucleoside analogs of duck hepatitis B virus polymerase mutants of the YMDD motif (submitted for publication).
4. Akbar S., Kajino K., Tanimoto K., Kurose K., Masumoto T., Michitaka K., Horiike N., Onji M. Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J. Hepatol. 26:1997;131-137.
5. Akbar S.M., Abe M., Masumoto T., Horiike N., Onji M. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells [In Process Citation]. J. Hepatol. 30:1999;755-764.
6. Aldrich C.E., Coates L., Wu T.-T., Newbold J., Tennant B.C., Summers J., Seeger C., Mason W.S. In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus. Virology. 172:1989;247-252.
7. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrell D.L.J., Brown N., Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1998;1670-1677.
8. Argentini C., La Sorsa V., Bruni R., D'Ugo E., Giuseppetti R., Rapicetta M. Hepadnavirus evolution and molecular strategy of adaptation in a new host. J. Gen. Virol. 80:1999;617-626.
9. Arts E., Wainberg M. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents. Chemother. 40:1996;527-540.
10. Aye, T.T., Bartholomeusz, A., Shaw, T., Bowden, S., Breschkin, A., Mc Millan, J., Angus, P., Locarnini, S., 1997. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26, 1148-1153.
11. Back N.K.T., Berkhout B. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents. Chemother. 41:1997;2484-2491.
12. Back N.K.T., Nijhuis M., Keulen W., Boucher C.A.B., Oude Essink B.B., van Kuilenburg A.B.P., van Gennip A.H., Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:1996;4040-4049.
13. Bartenschlager R., Schaller H. The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J. 7:1988;4185-4192.
14. Bartenschlager R., Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 11:1992;3413-3420.
15. Bartenschlager R., Junker-Niepmann M., Schaller H. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J. Virol. 64:1990;5324-5332.
16. Bartholomeusz A., Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int. Antivir. News. 5:1997;123-124.
17. Bartholomeusz A., Groenen L.C., Locarnini S.A. Clinical experience with famciclovir against hepatitis B virus. Intervirology. 40:1997;337-342.
18. Bartholomew M., Jansen R., Jeffers L., Reddy K., Johnson L., Bunzendahl H., Condreay L., Tzakis A., Schiff A., Brown N. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
19. Benn J., Su F., Doria M., Schneider R. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-jun N-terminal mitogen-activated protein kinases. J. Virol. 70:1996;4978-7985.
20. Block T.M., Lu X., Mehta A.S., Blumberg B.S., Tennant B., Ebling M., Korba B., Lansky D.M., Jacob G.S., Dwek R.A. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. 4:1998;610-614.
21. Bloomer J., Chan R., Sherman M., Ingraham P., DeHertog D. A preliminary study of Lobucavir for chronic hepatitis B. Hepatology (Abstr. 1199). 26 (N04, Pt2):1997;428A.
22. Böttcher B., Tsuji N., Takahashi H., Dyson M., Zhao S., Crowther R.A., Murray K. Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection. EMBO J. 17:1998;6839-6845.
23. Boyd M., Bacon T., Sutton D., Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob. Agents. Chemother. 31:1987;1238-1242.
24. Bréchot C., Pourcel C., Louise A., Rain B., Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature. 286:1980;533-535.
25. Bréchot C., Scotto J., Charnay P., Hadchouel M., Degos F., Trépo C., Tiollais P. Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet. i:1981;765-768.
26. Breiner K.M., Urban S., Schaller H. Carboxypeptidase D (gp180), a golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses. J. Virol. 72:1998;8098-8104.
27. Bridges, E., Cheng, Y., 1995. In: Boyer, J.L., Ockner, R.K. (Eds.), Use of novel b-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Prog. Liver Dis. 13, 231-245.
28. Bridges E.G., Dutschman G.E., Gullen E.A., Cheng Y.-C. Favorable interaction of b-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem. Pharmacol. 51:1996;731-736.
29. Bruss V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J. Virol. 71:1997;9350-9357.
30. Bruss V., Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc. Natl. Acad. Sci. USA. 88:1991;1059-1063.
31. Bruss V., Thomssen R. Mapping of a region of the large envelope protein required for hepatitis B virion maturation. J. Virol. 68:1994;1643-1650.
32. Bruss V., Vieluf K. Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J. Virol. 69:1995;6652-6657.
33. Cavanaugh V.J., Guidotti L., Chisari F.V. Interleukine-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71:1997;3236-3243.
34. Chang L.-J., Pryciak P., Ganem D., Varmus H.E. Biosynthesis of the reverse transcriptase of hepatitis B viruses involves de novo translation initiation not ribosomal frameshifting. Nature. 337:1989;364-368.
35. Chang L.-J., Hirsch R.C., Ganem D., Varmus H.E. Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J. Virol. 64:1990;5553-5558.
36. Chang C.-N., Doong S.-L., Zhou J.H., Beach J.W., Jeong L.S., Chu C.K., Tsai C.-H., Cheng Y.-C. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±) 2′,3′ dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:1992;13938-13942.
37. Chang M.-H., Chen C.-J., Lai M.-S., Hsu H.-M., Wu T.-C., Kong M.-S., Liang D.-C., Shau W.-Y., Chen D.-S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336:1997;1855-1859.
38. Chayama K., Suzuki Y., Kobayashi M., Kobayashi M., Tsubota A., Hashimoto M., Miyamo Y., Koike H., Kobayashi M., Koida I., Arase Y., Saito S., Murashima N., Ikeda K., Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-take-over by wild type after cessation of therapy. Hepatology. 27:1998;1711-1716.
39. Chen H.S., Kaneko S., Girones R., Anderson R.W., Hornbuckle W.E., Tennant B.C., Cote P.J., Gerin J.L., Purcell R.H., Miller R.H. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol. 67:1993;1218-1226.
40. Chisari F. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology. 22:1995;1316-1325.
41. Chu C., Ma T., Shanmuganathan K., Wang C., Xiang Y., Pai S., Yao G., Sommadossi J., Cheng Y. Use of 2′-fluoro-5-methyl-b-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents. Chemother. 39:1995;979-981.
42. Colgrove R., Simon G., Ganem D. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus gene product in cells permissive for viral replication. J. Virol. 63:1989;4019-4026.
43. Colledge D., Locarnini S., Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 26:1997;216-225.
44. Condreay L., Condreay J., Jansen R., Paff M., Averett D. cis-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob. Agents. Chemother. 40:1996;520-523.
45. Cullen J.M., Smith S.L., Davis M.G., Dunn S.E., Botteron C., Cecchi A., Linsey D., Linzey D., Frick L., Paff M.T., Goulding A., Biron K. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents. Chemother. 41:1997;2076-2082.
46. Dannaoui E., Trépo C., Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:1997;38-46.
47. Dejean A., Bougueleret L., Grzeschik K.H., Tiollais P. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature. 322:1986;70-72.
48. Delaney W.E., Isom H.C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology. 28:1998;1134-1146.
49. Dienstag J., Perillo R., Schiff E., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1995;1657-1661.
50. Doong S.-L., Tsai C.-H., Schinazi R.F., Liotta D.C., Cheng Y.-C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA. 88:1991;8495-8499.
51. Dutschman G.E., Bridges E.G., Liu S.-H., Gullen E., Guo X., Kukhanova M., Cheng Y.-C. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-b-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus b-D(+) nucleoside analogs in vitro. Antimicrob. Agents. Chemother. 42:1998;1799-1804.
52. Earnshaw D., Bacon T., Darlison S., Edmonds K., Perkins R., Vere Hodge R. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and Varicella-Zoster virus. Antimicrob. Agents. Chemother. 36:1992;2747-2757.
53. Eto T., Takahashi H. Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Nat. Med. 5:1999;577-581.
54. Fischer K.P., Tyrell D.L.J. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine((-)-b-L-2′,3′-dideoxy-3′-thiacytidine) in vitro. Antimicrob. Agents. Chemother. 40:1996;1957-1960.
55. Fontana R.J., Lok A.S.F. Combination therapy for chronic hepatitis B. Hepatology. 26:1997;234-237.
56. Fourel G., Trépo C., Bougueleret L., Henglein B., Ponzetto A., Tiollais P., Buendia M.A. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumors. Nature. 347:1990;294-298.
57. Fourel I., Cullen J.M., Saputelli J., Aldrich C.E., Schaffer P., Averett D.R., Pugh J., Mason W.S. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:1994;8321-8330.
58. Fourel I., Saputelli J., Schaffer P., Mason W.S. The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J. Virol. 68:1994;1059-1065.
59. Fu L., Cheng Y.-C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 55:1998;1567-1572.
60. Geissler M., Tokushige K., Chante C.C., Zurawski V.R., Wands J.R. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA based immunization. Gastroenterology. 112:1997;1307-1320.
61. Genovesi E.V., Lamb L., Medina I., Taylor D., Seifer M., Innaimo S., Colonno R.J., Standring D.N., Clark J.M. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents. Chemother. 42:1998;3209-3217.
62. Gilles P., Fey G., Chisari F. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J. Virol. 66:1992;3955-3960.
63. Gong S.S., Jensen A.D., Wang H., Rogler C.E. Duck hepatitis B virus integrations in LMH chicken hepatoma cells: identification and characterization of new episomally derived integrations. J. Virol. 69:1995;8102-8108.
64. Gong S.S., Jensen A.D., Rogler C.E. Loss and acquisition of duck hepatitis B virus integrations in lineages of LMH-D2 chicken hepatoma cells. J. Virol. 70:1996;2000-2007.
65. Gong S.S., Jensen A.D., Chang C.J., Rogler C.E. Double-stranded linear duck hepatitis B virus (DHBV) stably integrates at a higher frequency than wild-type DHBV in LMH chicken hepatoma cells. J. Virol. 73:1999;1492-1502.
66. Gong Z.J., De Meyer S., van Pelt J., Hertogs K., Depla E., Soumillion A., Fevery J., Yap S.H. Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infection. Hepatology. 29:1999;576-584.
67. Gray N.M., Marr C.L., Penn C.R., Cameron J.M., Bethell R.C. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem. Pharmacol. 50:1995;1043-1051.
68. Guilhot S., Guidotti L., Chisari F. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J. Virol. 67:1993;7444-7449.
69. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science. 284:1999;825-829.
70. Hantz O., Borel C., Trabaud C., Zoulim F., Dessolin J., Camplo M., Vlieghe P., Bouygues M., Trépo C., Kraus J.L. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob. Agents. Chemother. 41:1997;2579-2581.
71. Heathcote E.J., Jeffers L., Wright T., Sherman M., Perillo R., Sacks S., Carithers R., Rustgi V., Di Bisceglie A., Balan V., Murray A., Rooney J. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo controlled phase II studies. Hepatology (Abstr.). 28:1998;317A.
72. Heathcote J., Chan R., McHutchinson J., Lee W.M., Sherman M., Rutkiewicz V., De Hertog D. A phase 2 multicenter-study of oral lobucavir for treatment of chronic hepatitis B. Hepatology (Abstr.). 28:1998;318A.
73. Heijtink R., Paulij W., van Bergen P., van Roosmalen M., Rohm D., Eichentopf B., Muchmore E., de Man R., Osterhaus A. In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J. Gen. Virol. 80:1999;1529-1535.
74. Heise T., Guidotti L.G., Cavanaugh V.J., Chisari F.V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J. Virol. 73:1999;474-481.
75. Hino O., Shows T., Rogler C.E. Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation. Proc. Natl. Acad. Sci. USA. 83:1986;8338-8342.
76. Hino O., Ohtake K., Rogler C.E. Features of two hepatitis B virus (HBV) DNA integrations suggest mechanism of HBV integration. J.Virol. 63:1989;2638-2643.
77. Hirsch R.C., Loeb D.D., Pollack J.R., Ganem D. Cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J. Virol. 65:1991;3309-3316.
78. Hirsch R.C., Lavine J.E., Chang L.J., Varmus H.E., Ganem D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription. Nature. 344:1990;552-555.
79. Hoofnagle J.H., Di Bisceglie A.M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:1997;347-356.
80. Hsu T., Moroy T., Etiemble J., Louise A., Trépo C., Tiollais P., Buendia M. Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell. 55:1988;627-635.
81. Hu J., Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 93:1996;1060-1064.
82. Hu, J., Toft, D., Seeger, C., 1997. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J. 16, 59-68.
83. Huang J., Kwong J., Sun E.C., Liang T.J. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J. Virol. 70:1996;5582-5591.
84. Ilan E., Burakova T., Dagan S., Nussbaum O., Lubin I., Eren R., Ben-Moshe O., Arazi J., Berr S., Neville L., Yuen L., Mansour T.S., Gillard J., Eid A., Jurim O., Shouval D., Reisner Y., Galun E. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology. 29:1999;553-562.
85. Innaimo S.F., Seifer M., Bisacchi G.S., Standring D.N., Zahler R., Colonno R.J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents. Chemother. 41:1997;1444-1448.
86. Kajino K., Jilbert A., Saputelli J., Aldrich C., Cullen J., Mason W. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J. Virol. 68:1994;5792-5803.
87. Kay A., Mandart E., Trépo C., Galibert F. The HBV HBx gene expressed in E. coli is recognised by sera from hepatitis patients. EMBO J. 4:1985;1287-1292.
88. Kekule A.S., Lauer U., Weiss L., Luber B., Hofschneider P.H. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature. 361:1993;742-745.
89. Kock J., Schlicht H.G. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J. Virol. 67:1993;4867-4874.
90. Kock J., Theilmann L., Galle P., Schlicht H. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology. 23:1996;405-413.
91. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5 Å resolution if HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
92. Korba B., Boyd M. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents. Chemother. 40:1996;1282-1284.
93. Koziel M.G., Liang T.J. DNA vaccines and viral hepatitis: are we going around in circles. Gastroenterology. 112:1997;1410-1414.
94. Kuroki K., Cheung R., Marion P., Ganem D. A cell surface protein that binds avian hepatitis B virus particles. J. Virol. 68:1994;2091-2096.
95. Lai C.-L., Ching C.-K., Tung A.K.-M., Li E., Young J., Hill A., Wong B.C.-Y., Dent J., Wu P.-C. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 25:1997;241-244.
96. Lai C.L., Chine R.W., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., Wu P.C., Dent J.C., Barber J., Stephenson S.L., Gray F. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:1998;61-68.
97. Lambert F., Fernholz D., Sprengel R., Fourel I., Deléage G., Wildner G., Peyret C., Trépo C., Cova L., Will H. Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein. J. Virol. 64:1990;1290-1297.
98. Lanford R., Notvall L., Beames B. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:1995;4431-4439.
99. Lanford R., Notvall L., Lee H., Beames B. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J. Virol. 71:1997;2996-3004.
100. Lanford R.E., Chavez D., Brasky K.M., Burns R.B., Ricco-Hesse R. Isolation of a hepadnavirus from the woolly monkey, a new world primate. Proc. Natl. Acad. Sci. USA. 95:1998;5757-5761.
101. Lanford R.E., Kim Y.H., Lee H., Notvall L., Beames B. Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction [In Process Citation]. J. Virol. 73:1999;1885-1893.
102. Le Guerhier, F., Pichoud, C., Chevallier, M., Guerret, S., Liu, S.H., Trépo, C., Cheng, Y.C., Zoulim, F., 1999. Characterization of the antiviral activity of 2′, 3′-dideoxy-2′, 3′-didehydro-β-L-5-flourocytidine in the duck hepatitis B virus infection model (submitted for publication).
103. Le Seyec J., Chouteau P., Cannie I., Guguen-Guillouzo C., Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J. Virol. 73:1999;2052-2057.
104. Lee W. Drug-induced hepatotoxicity. N. Engl. J. Med. 333:1995;1118-1127.
105. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 337:1997;1733-1745.
106. Li J.-L., Tong S.-P. Characterization of a 120-kilodalton pre-S-binding protein as a candidate duck hepatitis B virus receptor. J. Virol. 70:1996;6029-6035.
107. Lin T.-S., Luo M.-Z., Liu M.-C., Pai S.-B., Dutschman G.-E., Cheng Y.-C. Antiviral activity of 2′,3′-dideoxy-b-L-5-Fluorocytidine (b-L-F-ddC) and 2′,3′-dideoxy-b-L-cytidine (b-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem. Pharmacol. 47:1994;171-174.
108. Lin E., Luscombe C., Wang Y., Shaw T., Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents. Chemother. 40:1996;413-418.
109. Lin E., Luscombe C., Colledge D., Wang Y.Y., Locarnini S. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents. Chemother. 42:1998;2132-2137.
110. Ling R., Harrison T.J. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus [In Process Citation]. J. Gen. Virol. 80:1999;601-606.
111. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., Harrison T.J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
112. Liu S.-H., Grove K.L., Cheng Y.-C. Unique metabolism of a novel antiviral l-nucleoside analog, 2′-fluoro-5-methyl-b-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob. Agents. Chemother. 42:1998;833-839.
113. Locarnini, S.A., Aye, T.T., Shaw, T., De Man, R., Angus, P.W., Mc Caughan, G.W., Bartholomeusz, A., 1997. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy following liver transplantation. Hepatology (Abstr. 958) 26.
114. Lu M., Hilken G., Kruppenbacher J., Kemper T., Schirmbeck R., Reimann J., Roggendorf M. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J. Virol. 73:1999;281-289.
115. Luscombe C., Pedersen J., Uren E., Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect of intrahepatic-viral DNA, RNA, and protein expression. Hepatology. 24:1996;766-773.
116. Maguire H.F., Hoeffler J.P., Siddiqui A. HBVX protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science. 252:1991;842-844.
117. Mancini M., Hadchouel M., Tiollais P., Pourcel C., Michel M. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing 'nonresponse to HBsAg'. J. Med. Virol. 39:1992;67-74.
118. Mason W.S. The problem of antiviral therapy for chronic hepadnavirus infection. J. Hepatol. 17(Suppl. 3):1993;S137-S142.
119. Mason W.S., Taylor J.M. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections. Hepatology. 9:1989;635-645.
120. Mason W.S., Seal G., Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J. Virol. 36:1980;829-836.
121. Mason W.S., Cullen J., Saputelli J., Wu T., Liu C., London W., Lustbader E., Schaffer P., O'Connell A., Fourel I., Aldrich C., Jilbert A. Characterization of the antiviral activity of 2′carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology. 19:1994;398-411.
122. Mason W.S., Cullen J., Moraleda G., Saputelli J., Aldrich C.E., Miller D.S., Tennant B., Frick L., Averett D., Condreay L.D., Jilbert A.R. Lamivudine therapy of WHV-infected woodchucks. Virology. 245:1998;18-32.
123. Melegari M., Scaglioni P.P., Wands J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 27:1998;628-633.
124. Merle P., Levy R., Vitvitski L., Chevallier M., Buendia M.A., Trépo C. Efficacy of interferon alpha in primary prevention of preneoplastic lesions in a transgenic murine model of hepatocellular carcinoma related to the interaction between woodchuck hepatitis viruses and c-myc oncogene. Gastroenterol. Clin. Biol. 21:1997;459-465.
125. Moraleda G., Saputelli J., Aldrich C.E., Averett D., Condreay L., Mason W.S. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71:1997;9392-9399.
126. Nagai H., Pineau P., Tiollais P., Buendia M.A., Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene. 14:1997;2927-2933.
127. Nair V., Jahnke T. Antiviral activities of isomeric dideoxynucleosides of D- and L-related stereochemistry. Antimicrob. Agents. Chemother. 39:1995;1017-1029.
128. Nassal M. The arginine rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive strand DNA synthesis but not for virus assembly. J. Virol. 66:1992;4107-4116.
129. Nevens F., Main J., Honkoop P., Tyrrell D.L., Barber J., Sullivan M.T., Fevery J., De Man R., Thomas H.C. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology. 113:1997;1258-1263.
130. Nicoll A.J., Colledge D.L., Toole J.J., Angus P.W., Smallwood R.A., Locarnini S.A. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob. Agents. Chemother. 42:1998;3130-3135.
131. Niesters H.G., Honkoop P., Haagsma E.B., de Man R.A., Schalm S.W., Osterhaus A.D. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177:1998;1382-1385.
132. Norder H., CouroucZ A.-M., Magnius L. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 198:1994;489-503.
133. Nowak M., Bonhoeffer S., Hill A., Boehme R., Thomas H., McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA. 93:1996;4398-4402.
134. Offensperger W., Offensperger S., Walter E., Teubner K., Igloi G., Blum H., Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 12:1993;1257-1262.
135. Ono-Nita S.K., Kato N., Shiratori Y., Masaki T., Lan K.H., Carrilho F.J., Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection [In Process Citation]. Hepatology. 29:1999;939-945.
136. Pai S., Liu S., Zhu Y., Chu C., Cheng Y. Inhibition of hepatitis B virus by a novel l-nucleoside, 2′-fluoro-5-methyl-b-L-arabinofuranosyl uracil. Antimicrob. Agents. Chemother. 40:1996;380-386.
137. Parker W., Cheng Y. Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 6:1994;57-61.
138. Perillo, R., Rakela, J., Martin, P., Levy, G., Schiff, E., Wright, T., Dienstag, J., Gish, R., Villeneuve, J., Caldwell, S., Brown, N., Self, P., 1997a. Long-term lamivudine therapy of patients with recurrent hepatitis B post-liver transplantation. Hepatology (Abstr. 196) 26.
139. Perillo, R., Rakela, J., Martin, P., Wright, T., Levy, G., Schiff, E., Dienstag, J., Gish, R., Dickson, R., Adams, P., Brown, N., Self, P., 1997b. Lamivudine for suppression and/or prevention of hepatitis B when given pre-/post-liver transplantation (OLT). Hepatology (Abstr. 526) 26.
140. Perrillo R., Rakela J., Dienstag J., Levy G., Martin P., Wright T., Caldwell S., Schiff E., Gish R., Villeneuve J.P., Farr G., Anschuetz G., Crowther L., Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology. 29:1999;1581-1586.
141. Pichoud C., Seignères B., Wang Z., Trépo C., Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology. 29:1999;230-237.
142. Pichoud, C., Berby, F., Stuyver, L., Petit, M.A., Trepo, C., Zoulim, F., 1999. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J. Hepatol. (in press).
143. Pol S., Driss F., Michel M., Nalpas B., Berthelot P., Bréchot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet. 344:1994;342.
144. Pourquier P., Jensen A.D., Gong S.S., Pommier Y., Rogler C.E. Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Nucleic Acids Res. 27:1999;1919-1925.
145. Radziwill G., Tucker W., Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNAseH activity. J. Virol. 64:1990;613-620.
146. Rajagopalan P., Boudinot F., Chu C., Tennant B., Baldwin B., Schinazi R. Pharmacokinetics of (-) 2′,3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob. Agents. Chemother. 40:1996;642-645.
147. Richman D.D. Drug resistance and its implications in the management of HIV infection. Antiviral. Ther. 2(supplement 4):1997;41-58.
148. Rollier C., Sunyach C., Barraud L., Madani N., Jamard C., Trépo C., Cova L. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology. 116:1999;658-665.
149. Roychoudhury S., Faruqi A.F., Shih C. Pregenomic RNA encapsidation analysis of eleven missense and nonsense polymerase mutants of human hepatitis B virus. J. Virol. 65:1991;3617-3624.
150. Ryu C.J., Gripon P., Park H.R., Park S.S., Kim Y.K., Guguen-Guillouzo C., Yoo O.J., Hong H.J. In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen. J. Med. Virol. 52:1997;226-233.
151. Scaglioni P., Melegari M., Takahashi M., Roy Chowdhury J., Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology. 24:1996;1010-1017.
152. Schaller H., Fischer M. Transcriptionnal control of hepadnavirus gene expression. Mason W.S., Seeger C. Current Topics in Microbiology and Immunology. Hepadnaviruses. Molecular Biology and Pathogenesis. 1991;41-60 Springer-Verlag, Berlin.
153. Schek N., Fisher M., Schaller H. The hepadnaviral X protein. Mc Lahlan A.
154. Schirmbeck R., Bohm W., Ando K., Chisari F., Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69:1995;5929-5934.
155. Schultz U., Chisari F.V. Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes. J. Virol. 73:1999;3162-3168.
156. Schultz U., Summers J., Staeheli P., Chisari F.V. Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes [In Process Citation]. J. Virol. 73:1999;5459-5465.
157. Seeger C. The hepatitis B virus X protein: the quest for a role in viral replication and pathogenesis. Hepatology. 25:1997;496-498.
158. Seeger C., Mason W.S. Hepadnavirus replication and approaches to antiviral therapy. Doerfler W., Bohm P. Virus Strategies, Ch. 4. 1993;77-93 VCH, Germany.
159. Seeger C., Ganem D., Varmus H.E. The nucleotide sequence of an infectious molecularly cloned genome of ground squirrel hepatitis virus. J. Virol. 51:1984;367-375.
160. Seeger C., Ganem D., Varmus H.E. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science. 232:1986;477-484.
161. Seifer M., Hamatake R.K., Colonno R.J., Standring D.N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents. Chemother. 42:1998;3200-3208.
162. Seignères B., Pichoud C., Si Ahmed S., Hantz O., Trépo C., Zoulim F. Non response to famciclovir therapy in immune competent patients with chronic hepatitis B is associated with complex variability of the polymerase gene. Hepatology (Abstr.). 28:1998;586A.
163. Seignères B., Pichoud, C., SiAhmed, S., Hantz, O., Trepo, C., Zoulim, F., 1999. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B (submitted for publication).
164. Seto E., Zhou D.X., Peterlin B.M., Yen B.T.S. Trans-activation by the hepatitis B virus X protein shows cell-type specificity. Virology. 173:1989;764-766.
165. Severini A., Liu X.-Y., Wilson J., Tyrell D. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-b-L-2′,3′-dideoxy-3′-thyacytidine. Antimicrob. Agents. Chemother. 39:1995;1430-1435.
166. Shaw T., Amor P., Civitico G., Boyd M., Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents. Chemother. 38:1994;719-723.
167. Shaw T., Mok S., Locarnini S. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 24:1996;996-1002.
168. Si Ahmed, S., Tavan, D., Berby, F., Pichoud, C., Seignères, B., Merle, P., Stuyver, L., Trepo, C., Zoulim, F., 1999. Dynamic of drug resistant mutants in patients with chronic hepatitis B receiving lamivudine therapy (submitted for publication).
169. Sitterlin D., Lee T.H., Prigent S., Tiollais P., Butel J.S., Transy C. Interaction of the UV-damaged DNA-binding protein with hepatitis B virus X protein is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants. J. Virol. 71:1997;6194-6199.
170. Sitterlin, D., et al., 1999. Unpublished data.
171. Sprengel R., Kaleta E.F., Will H. Isolation and characterization of a hepatitis B virus endemic in herons. J. Virol. 62:1988;3832-3839.
172. Staschke K., Colacino J. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J. Virol. 68:1994;8265-8269.
173. Stuyver L., Wyseur A., Rombout A., Louwagie J., Scarcez T., Verhofstede C., Rimland D., Schinazi R.F., Rossau R. Line Probe Assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents. Chemother. 41:1997;284-291.
174. Stuyver, L., Van Geyt, C., De Gendt, S., Van Reybroeck, G., Zoulim, F., Lerous-Roels, G., Rossau, R. A line probe assay for monitoring drug-resistance in HBV-infected patients during antiviral therapy (submitted for publication).
175. Su F., Schneider R. Hepatitis B virus HBx protein activates transcription factor NF-kB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J. Virol. 70:1996;4558-4566.
176. Summers J. Three recently described animal virus models for human hepatitis B virus. Hepatology. 1:1981;179-183.
177. Summers J., Mason W.S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 29:1982;403-415.
178. Summers J., Smolec J.M., Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc. Natl. Acad. Sci. USA. 75:1978;4533-4537.
179. Summers J., Smith P.M., Horwich A.L. Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:1990;2819-2824.
180. Sunyach C., Chassot S., Jamard C., Kay A., Trépo C., Cova L. In vivo selection of duck hepatitis B virus pre-S variants which escape from neutralization. Virology. 234:1997;291-299.
181. Sunyach C., Rollier C., Robaczewska M., Borel C., Barraud L., Kay A., Trépo C., Will H., Cova L. Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction. J. Virol. 73:1999;2569-2575.
182. Tavis J.E., Ganem D. Expression of functional hepatitis B virus polymerase in yeast reveals it to be the sole viral protein required for correct initiation of reverse transcription. Proc. Natl. Acad. Sci. USA. 90:1993;4107-4111.
183. Tavis J.E., Perri S., Ganem D. Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signals and employs a novel strand transfer. J. Virol. 68:1994;3536-3543.
184. Tennant B., Jacob J., Graham L., Peek S., Korba B., Gerin J., Witcher J., Boudinot F., Du J., Chu C. Pharmacokinetic and pharmacodynamic studies of 1-(2-fluoro-5-methyl-b-L-arabinofuranosyl)uracil (L-FMAU) in the woodchuck model of hepatitis B virus (HBV) infection. Antivir. Res. (Abstr. 36). 34:1997;52.
185. Terradillos O., Pollicino T., Lecoeur H., Tripodi M., Gougeon M.L., Tiollais P., Buendia M.A. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene. 17:1998;2115-2123.
186. Thio C.L., Carrington M., Marti D., O'Brien S.J., Vlahov D., Nelson K.E., Astemborski J., Thomas D.L. Class II HLA alleles and hepatitis B virus persistence in African Americans. J. Infect. Dis. 179:1999;1004-1006.
187. Thursz M.R., Kwiatkowski D., Allsopp C.E., Greenwood B.M., Thomas H.C., Hill A.V. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia [see comments]. N. Engl. J. Med. 332:1995;1065-1069.
188. Tillmann, H.L., Trautwein, C., Bock, T., Glowenka, M., Krüger, M., Böker, K., Jäckel, E., Pichlmayr, R., Condreay, L., Bruns, I., Deslauriers, M., Gauthier, J., Manns, M., 1997. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology (Abstr. 1202) 26.
189. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
190. Toh H., Hayashida H., Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature. 305:1983;827-829.
191. Trépo C., Jezek P., Atkinson G., Boon R. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology (Abstr. 247). 24:1996;188A.
192. Triyatni M., Jilbert A.R., Qiao M., Miller D.S., Burrell C.J. Protective efficacy of DNA vaccines against duck hepatitis B virus infection. J. Virol. 72:1998;84-94.
193. Tsiang M., Rooney J.F., Toole J.J., Gibbs C.S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology. 29:1999;1863-1869.
194. Tsiquaye K., Slomka M., Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J. Med. Virol. 42:1994;306-310.
195. Tsiquaye K., Sutton D., Maung M., Boyd M. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antiviral. Chem. Chemother. 7:1996;153-159.
196. Turin F., Borel C., Benchaib M., Kay A., Jamard C., Guguen-Guillouzo C., Trépo C., Hantz O. n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J. Virol. 70:1996;2691-2696.
197. Tuttleman J., Pourcel C., Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell. 47:1986;451-460.
198. Urban M., McMillan D.J., Canning G., Newell A., Brown E., Mills J.S., Jupp R. In vitro activity of hepatitis B virus polymerase: requirement for distinct metal ions and the viral epsilon stem-loop. J. Gen. Virol. 79:1998;1121-1131.
199. Urban S., Breiner K.M., Fehler F., Klingmüller U., Schaller H. Avian hepatitis B virus infection is initiated by the interaction of a distinct pre-S subdomain with the cellular receptor gp 180. J. Virol. 72:1998;8089-8097.
200. Van Draanen N., Tisdale M., Parry N., Jansen R., Dornsife R., Tuttle J., Averett D., Koszalka G. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob. Agents. Chemother. 38:1994;868-871.
201. Vere Hodge R., Perkins R. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents. Chemother. 33:1989;223-229.
202. von Weizsäcker F., Blum H., Wands F. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from single DNA template. Biochem. Biophys. Res. Commun. 189:1992;743-748.
203. von Weizsäcker G., Wieland S., Köck J., Offensperger W.-B., Offensperger S., Moradpour D., Blum H.E. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology. 26:1997;251-255.
204. Wainberg M.A., Drosopoulos W.C., Salomon H., Hsu M., Borkow G., Parniak M.A., Gu Z., Song Q., Manne J., Islam S., Castriota G., Prasad V.R. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 271:1996;1282-1285.
205. Wang H.P., Rogler C.E. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J. Virol. 65:1991;2381-2392.
206. Wang G.H., Seeger C. The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis. Cell. 71:1992;633-670.
207. Wang G.H., Seeger C. A novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67:1993;6507-6512.
208. Wang, J., Chenivesse, X., Henglein, B., Bréchot, C., 1990. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343, 555-557.
209. Wang G.H., Zoulim F., Leber E., Kitson J., Seeger C. The role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J. Virol. 68:1994;8437-8442.
210. Wang H.P., Zhang L., Dandri M., Rogler C.E. Antisense downregulation of N-myc1 in woodchuck hepatoma cells reverses the malignant phenotype. J. Virol. 72:1998;2192-2198.
211. Wright Witcher J., Boudinot F.D., Baldwin B.H., Ascenzi M.A., Tennant B.C., Du J.F., Chu C.K. Pharmacokinetics of 1-(2-fluoro-5-methyl-b-L-arabinofuranosyl)Uracil in woodchucks. Antimicrob. Agents. Chemother. 41:1997;2184-2187.
212. Wu T.-T., Coates L., Aldrich C.E., Summers J., Mason W.S. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology. 175:1990;255-261.
213. Xiong X., Flores C., Yang H., Toole J.J., Gibbs C.S. Mutations in hepatitis B DNA polymerase asssociatedd with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology. 28:1998;1669-1673.
214. Xiong Y., Eickbush T. Origin and evolution of retroelements based upon their reverse transcriptase sequence. EMBO J. 9:1990;3353-3362.
215. Zhu Y.-L., Dutschman G.E., Liu S.-H., Bridges E.G., Cheng Y.-C. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-b-L(-)-5-fluorocytidine. Antimicrob. Agents. Chemother. 42:1998;1805-1810.
216. Zoulim F. Improving hepatitis B virus therapy - new inhibitors of reverse transcriptase. Int. Antivir. News. 5:1997;110-112.
217. Zoulim F., Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:1994;6-13.
218. Zoulim F., Trépo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 29:1998;151-168.
219. Zoulim F., Saputelli J., Seeger C. Woodchuck hepatitis virus X protein is required for viral replication in vivo. J. Virol. 68:1994;2026-2030.
220. Zoulim F., Dannaoui E., Borel C., Hantz O., Lin T.-S., Liu S.-H., Trépo C., Cheng Y.-C. 2′,3′-dideoxy-b-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40:1996;448-453.
221. zu Putlitz J., Lanford R.E., Carlson R.I., Notvall L., de la Monte S.M., Wands J.R. Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. J. Virol. 73:1999;4188-4196.
222. zu Putlitz J., Skerra A., Wands J.R. Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion. Biochem. Biophys. Res. Commun. 255:1999;785-791.
223. zu Putlitz J., Yu Q., Burke J.M., Wands J.R. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J. Virol. 73:1999;5381-5387.